Nano-X Imaging (NNOX) FDA Submission a 'Significant Regulatory Step' - Cantor Fitzgerald

Cantor Fitzgerald analyst Steven Halper reiterated an Overweight rating and $45.00 price target on Nano-X Imaging (NASDAQ: NNOX) announced that it submitted a 510(k) application to the FDA for the first version of its multi-source Nanox.ARC 3-D digital tomosynthesis system.

"We believe the submission marks a significant regulatory step in the company efforts to address an unmet need for accessible and cost-effective medical imaging," the analyst commented.

The analyst continues to assume that NNOX will deploy its initial 15,000 Nanox.ARC systems by the end of 2024.

For an analyst ratings summary and ratings history on Nano-X Imaging click here. For more ratings news on Nano-X Imaging click here.

Shares of Nano-X Imaging closed at $27.98 yesterday.

You May Also Be Interested In

• Nanox.AI Optimizes Medical Imaging AI Application Framework for Intel Core Ultra Processors with OpenVINO
• Nanox.AI tunes medical imaging AI for Intel Core Ultra chips
• Birkenstock Holding plc (BIRK) PT Raised to $44 at Morgan Stanley